{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:13:19Z","timestamp":1772903599540,"version":"3.50.1"},"reference-count":50,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.21290","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T16:30:53Z","timestamp":1581697853000},"page":"e1921290","source":"Crossref","is-referenced-by-count":30,"title":["Evaluation of the Association of Perioperative <i>UGT1A1<\/i> Genotype\u2013Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma"],"prefix":"10.1001","volume":"3","author":[{"given":"Daniel V. T.","family":"Catenacci","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Chase","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Lomnicki","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[{"name":"Department of Health Studies, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"de Wilton Marsh","sequence":"additional","affiliation":[{"name":"Northshore University Health System, Evanston, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murtuza M.","family":"Rampurwala","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Orland Park, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Narula","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, New Lennox, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Alpert","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namrata","family":"Setia","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Yuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uzma D.","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Center for Endoscopic Research and Therapeutics, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Peterson","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Moore","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Kipping-Johnson","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Orland Park, Illinois"},{"name":"University of Chicago Medicine, New Lennox, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugne","family":"Markevicius","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gordon","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenisha","family":"Allen","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Racette","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven B.","family":"Maron","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"},{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Yi","family":"Liao","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blase N.","family":"Polite","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Turaga","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek N.","family":"Prachand","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin K.","family":"Roggin","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell C.","family":"Posner","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"issue":"6","key":"zoi190800r1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.v68.6","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"7517","key":"zoi190800r2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma.","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"7636","key":"zoi190800r3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma.","volume":"541","author":"Cancer Genome Atlas Research Network","year":"2017","journal-title":"Nature"},{"issue":"11","key":"zoi190800r4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1046\/j.1365-2168.1998.00940.x","article-title":"Classification of adenocarcinoma of the oesophagogastric junction.","volume":"85","author":"Siewert","year":"1998","journal-title":"Br J Surg"},{"key":"zoi190800r5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur J Cancer"},{"key":"zoi190800r6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1756-8722-6-66","article-title":"Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.","volume":"6","author":"Sehdev","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"1","key":"zoi190800r7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi190800r8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10184","key":"zoi190800r9","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial.","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"zoi190800r10","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/jnci\/djt270","article-title":"Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis.","volume":"105","author":"Oba","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"zoi190800r11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/archsurg.2009.115","article-title":"Assessment of criteria and clinical significance of circumferential resection margins in esophageal cancer.","volume":"144","author":"Deeter","year":"2009","journal-title":"Arch Surg"},{"issue":"6","key":"zoi190800r12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1097\/PAS.0b013e31821a5692","article-title":"How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus.","volume":"35","author":"Verhage","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"zoi190800r13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1072-7515(02)01116-X","article-title":"Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection?","volume":"194","author":"Martin","year":"2002","journal-title":"J Am Coll Surg"},{"issue":"7","key":"zoi190800r14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.v98:7","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"issue":"11","key":"zoi190800r15","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations.","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"3","key":"zoi190800r16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","article-title":"Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.","volume":"18","author":"Cunningham","year":"2017","journal-title":"Lancet Oncol"},{"issue":"27","key":"zoi190800r17","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1200\/JCO.2014.55.5243","article-title":"Optimal management of esophageal adenocarcinoma: should we be CROSS?","volume":"32","author":"Smyth","year":"2014","journal-title":"J Clin Oncol"},{"key":"zoi190800r18","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1200\/EDBK_236827","article-title":"Gastroesophageal junction adenocarcinoma: is there an optimal management?","volume":"39","author":"Lin","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"zoi190800r19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1470-2045(07)70244-9","article-title":"PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.","volume":"8","author":"Lordick","year":"2007","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi190800r20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2967\/jnumed.110.085803","article-title":"(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.","volume":"52","author":"zum B\u00fcschenfelde","year":"2011","journal-title":"J Nucl Med"},{"issue":"15","key":"zoi190800r21","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2018.36.15_suppl.4012","article-title":"Survival outcomes from CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.","volume":"36","author":"Goodman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi190800r22","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1200\/JCO.2019.37.15_suppl.4018","article-title":"PET-directed combined modality therapy for gastroesophageal junction cancer: first results of the prospective MEMORI trial.","volume":"37","author":"Lorenzen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi190800r23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","article-title":"Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial.","volume":"17","author":"Al-Batran","year":"2016","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi190800r24","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/jco.2014.32.15_suppl.4073","article-title":"HER-FLOT: trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the AIO Gastric Cancer Study Group.","volume":"32","author":"Hofheinz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"zoi190800r25","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi190800r26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1093\/annonc\/mdl317","article-title":"Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil\/leucovorin in patients with untreated metastatic gastric adenocarcinoma.","volume":"18","author":"Lee","year":"2007","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi190800r27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/jco.2015.33.3_suppl.177","article-title":"FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).","volume":"33","author":"Lockhart","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi190800r28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/01213011-200505000-00004","article-title":"Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.","volume":"15","author":"Innocenti","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"24","key":"zoi190800r29","first-page":"6921","article-title":"Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res"},{"issue":"8","key":"zoi190800r30","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","article-title":"Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.","volume":"22","author":"Innocenti","year":"2004","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi190800r31","doi-asserted-by":"publisher","first-page":"5151","DOI":"10.1158\/1078-0432.CCR-03-0548","article-title":"Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.","volume":"10","author":"Rouits","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"10","key":"zoi190800r32","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/cncr.31938","article-title":"A UGT1A1 genotype\u2013guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"issue":"15","key":"zoi190800r33","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2019.37.15_suppl.4050","article-title":"Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing \u2018gFOLFIRINOX\u2019 for gastroesophageal adenocarcinoma (GEA).","volume":"37","author":"Catenacci","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi190800r34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.v99.4","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing.","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"zoi190800r35","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","article-title":"Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.","volume":"29","author":"Ychou","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi190800r36","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ijc.v130.7","article-title":"Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.","volume":"130","author":"Homann","year":"2012","journal-title":"Int J Cancer"},{"issue":"15","key":"zoi190800r37","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1200\/jco.2010.28.15_suppl.4075","article-title":"Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: safety and response results from a multicenter phase II trial.","volume":"28","author":"Ferri","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi190800r38","first-page":"868","article-title":"Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer.","volume":"16","author":"Biffi","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"11","key":"zoi190800r39","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1093\/annonc\/mds129","article-title":"Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)dagger.","volume":"23","author":"Thuss-Patience","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi190800r40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials.","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"282","key":"zoi190800r41","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"25","key":"zoi190800r42","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi190800r43","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.","volume":"114","author":"Stein","year":"2016","journal-title":"Br J Cancer"},{"issue":"8","key":"zoi190800r44","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101.","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi190800r45","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/jso.v117.3","article-title":"Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: a pilot study.","volume":"117","author":"de W Marsh","year":"2018","journal-title":"J Surg Oncol"},{"issue":"5","key":"zoi190800r46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi190800r47","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1158\/1078-0432.CCR-16-1012","article-title":"Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.","volume":"23","author":"Toffoli","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi190800r48","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.molonc.2014.09.011","article-title":"Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity.","volume":"9","author":"Catenacci","year":"2015","journal-title":"Mol Oncol"},{"issue":"13","key":"zoi190800r49","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/S1470-2045(15)00224-7","article-title":"Expansion platform type II: testing a treatment strategy.","volume":"16","author":"Catenacci","year":"2015","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi190800r50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaoncol.2015.4191","article-title":"Perspectives on cost and value in cancer care.","volume":"2","author":"Saltz","year":"2016","journal-title":"JAMA Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2760897\/catenacci_2020_oi_190800.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T15:01:06Z","timestamp":1585753266000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2760897"}},"subtitle":["A Phase 2 Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.21290","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]}}}